A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

Inclusion Criteria:

- Over 18 years old.

- Advanced cancer potentially sensitive to single agent docetaxel; ie.. locally advanced
or metastatic breast cancer, locally advanced non-small cell lung cancer, hormone
refractory metastatic prostate cancer, other tumor type with no standard treatment.

- ECOG performance status of 0-2 and Karnofsky Score of 100-70.

Exclusion Criteria:

- Patients who have more effective therapy available than single agent docetaxel for the
malignancy.

- Pregnancy or lactation.

- Intolerance to any antineoplastic agents belonging to the taxoid family.

- Hypersensitivity to drugs formulated with polysorbate 80.

- Active infection.

- Prior anticancer therapy within 30 days prior to the first day of study treatment.

- Participation in another experimental drug study within 30 days prior to the first day
of study treatment.